Studies have demonstrated a significant elevation of ET-1 levels during the treatment of patients across various types of cancers (Aliabadi et al., 2022; Tapia and Niechi, 2019; Rosanò and Bagnato, 2016). This evidence concerns the gene EDN1 and cancer.